Phase I Clinical Trial Completes Using Cell Line Expertise at Cobra Biologics

News   Apr 03, 2017 | Original story from Cobra Biologics

 
Phase I Clinical Trial Completes Using Cell Line Expertise at Cobra Biologics

Peter Coleman, CEO of Cobra Biologics

 
 
 

RELATED ARTICLES

Artificial Cellular Compartments Built

News

How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.

READ MORE

XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery Services

News

XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.

READ MORE

BioAscent Establishes Integrated Drug Discovery Services Offering

News

Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Analysis & Separations Drug Discovery Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE